Essential Insights
Three authors—Chen, Tan, and Zhang—are identified as equal contributors to this work.
Research spans oncology, breast surgery, dermatology, molecular biology, and cancer precision medicine.
Institutions across Guangzhou, Shenzhen, Shanwei, Macao, and Stockholm contribute to the collaboration.
The affiliations connect clinical oncology centers with academic and interdisciplinary research groups.
A correction, not a new treatment
An author correction updates the scientific record. The available notice information identifies researchers’ equal contributions and their institutional affiliations. It does not specify what text or data changed. Therefore, it would be misleading to describe a particular correction or claim that it alters the study’s findings.
Why bispecific antibodies matter
The article examines patents and medical uses for bispecific antibodies. These engineered medicines can bind to two targets, a feature that may help researchers direct treatment more precisely. However, a patent landscape maps inventions; it does not prove that a therapy is safe, effective or available to patients.
Promise, with practical limits
For patients, more targeted treatments could eventually offer new options and improve quality of life. Yet development takes time. Researchers must test benefits, risks and access, while patent rights can shape who develops a medicine and when it reaches the public. Corrections also matter: Clear records help readers assess research and follow progress responsibly.
Stay Ahead with the Latest Tech Trends
Learn how the Internet of Things (IoT) is transforming everyday life.
Access comprehensive resources on space and science by visiting NASA.
Sci-BioV1
